About: Optimizing targets and therapeutics in high risk and refractory multiple myeloma

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Optimizing targets and therapeutics in high risk and refractory multiple myeloma Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Projekt, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/domain/vavai/Projekt
rdfs:seeAlso	http://www.cemit.at/projekte/eu-fp7-optatio.html http://www.isvav.cz/projectDetail.do?rowId=7E12070
Description	Multiple myeloma (MM) is an incurable disease with rapidly growing prevalence and poor prognosis. Consequently, it is the goal of OPTATIO consortium to seek out novel strategies for the development of novel diagnostic and therapeutic options. MM pathogenesis involves not only genetic changes within the tumour cells but also the emergence of supportive conditions by the bone marrow microenvironment (BMM). It is the goal of the project to establish preclinical in vitro and in vivo models of MM that include functionally relevant elements of the BMM. OPTATIO will analyse clinical data to correlate the presence of particular MM-BMM interactions with pathogenesis of MM with its intrinsic therapy resistance as well as with disease relapse due to development of acquired drug resistance. (en) Multiple myeloma (MM) is an incurable disease with rapidly growing prevalence and poor prognosis. Consequently, it is the goal of OPTATIO consortium to seek out novel strategies for the development of novel diagnostic and therapeutic options. MM pathogenesis involves not only genetic changes within the tumour cells but also the emergence of supportive conditions by the bone marrow microenvironment (BMM). It is the goal of the project to establish preclinical in vitro and in vivo models of MM that include functionally relevant elements of the BMM. OPTATIO will analyse clinical data to correlate the presence of particular MM-BMM interactions with pathogenesis of MM with its intrinsic therapy resistance as well as with disease relapse due to development of acquired drug resistance.
Title	Optimizing targets and therapeutics in high risk and refractory multiple myeloma (en) Optimizing targets and therapeutics in high risk and refractory multiple myeloma
skos:notation	7E12070
http://linked.open...avai/cep/aktivita	Subvention of the projects of the Seventh Framework Programme of the European Community for research, technological development including demonstration activities (FP7) according to the Czech law 171/2007 Sb.
http://linked.open...kovaStatniPodpora	http://linked.opendata.cz/resource/domain/vavai/projekt/7E12070/celkovaStatniPodpora
http://linked.open...ep/celkoveNaklady	http://linked.opendata.cz/resource/domain/vavai/projekt/7E12070/celkoveNaklady
http://linked.open...datumDodatniDoRIV	2015-02-16 (xsd:date)
http://linked.open...i/cep/druhSouteze	RP - Spolufinancování programu ES
http://linked.open...ep/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open.../cep/fazeProjektu	100527161
http://linked.open...ai/cep/hlavniObor	FD - Onkologie a hematologie
http://linked.open...vai/cep/kategorie	ZV - Základní výzkum
http://linked.open.../cep/klicovaSlova	zde zapsat 1 klíčové slovo, další přidat do dalších řádků; multiple myeloma; bone marrow microenvironment; drug discovery (en)
http://linked.open...ep/partnetrHlavni	Lékařská fakulta
http://linked.open...inujicichPrijemcu	0 (xsd:int)
http://linked.open...cep/pocetPrijemcu	1 (xsd:int)
http://linked.open...ocetSpoluPrijemcu	0 (xsd:int)
http://linked.open.../pocetVysledkuRIV	3 (xsd:int)
http://linked.open...enychVysledkuVRIV	3 (xsd:int)
http://linked.open...lneniVMinulemRoce	2013-03-20 (xsd:date)
http://linked.open.../prideleniPodpory	http://linked.opendata.cz/resource/domain/vavai/cep/prideleniPodpory/MSMT-1840%2F2013-310
http://linked.open...iciPoslednihoRoku	2014
http://linked.open...atUdajeProjZameru	2014
http://linked.open...usZobrazovaneFaze	DRRVK
http://linked.open...ai/cep/typPojektu	P - Projekt výzkumu a vývoje financovaný ze státního rozpočtu
http://linked.open...ep/ukonceniReseni	2014-12-31 (xsd:date)
http://linked.open.../cep/vedlejsiObor	FR - Farmakologie a lékárnická chemie FP - Ostatní lékařské obory
http://linked.open...ep/zahajeniReseni	2012-01-01 (xsd:date)
http://linked.open...tniCyklusProjektu	ZBK
http://linked.open...n/vavai/cep/vyzva	http://linked.opendata.cz/resource/domain/vavai/cep/vyzva/FP7-HEALTH-2011-two-stage
http://linked.open.../cep/klicoveSlovo	bone marrow microenvironment další přidat do dalších řádků multiple myeloma zde zapsat 1 klíčové slovo
is http://linked.open...vavai/riv/projekt of	Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance Gain(1)(q21) is an Unfavorable Genetic Prognostic Factor for Patients With Relapsed Multiple Myeloma Treated With Thalidomide but Not for Those Treated With Bortezomib Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma
is http://linked.open...vavai/cep/projekt of	http://linked.opendata.cz/resource/domain/vavai/cep/ucast/7E12070/2012/orjk%3A14110 http://linked.opendata.cz/resource/domain/vavai/cep/ucast/7E12070/2013/orjk%3A14110 http://linked.opendata.cz/resource/domain/vavai/cep/ucast/7E12070/2014/orjk%3A14110

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 112 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software